Zhejiang Jolly Pharmaceutical Co.,LTD

SZSE:300181 Stock Report

Market Cap: CN¥8.6b

Zhejiang Jolly PharmaceuticalLTD Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Zhejiang Jolly PharmaceuticalLTD.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth19.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

Aug 30
It's A Story Of Risk Vs Reward With Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Jul 29
We Ran A Stock Scan For Earnings Growth And Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) Passed With Ease

Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

May 13
Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Held Back By Insufficient Growth Even After Shares Climb 28%

A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

May 08
A Look At The Fair Value Of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181)

There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

Mar 01
There's No Escaping Zhejiang Jolly Pharmaceutical Co.,LTD's (SZSE:300181) Muted Earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Zhejiang Jolly PharmaceuticalLTD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SZSE:300181 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/20242,359481245381N/A
3/31/20242,120428145294N/A
12/31/20231,942383157288N/A
9/30/20231,926356162349N/A
6/30/20231,922336137310N/A
3/31/20231,86130291245N/A
1/1/20231,805273141319N/A
9/30/20221,72325258260N/A
6/30/20221,65522875290N/A
3/31/20221,55720474290N/A
1/1/20221,457179104252N/A
9/30/20211,400158234319N/A
6/30/20211,322145269336N/A
3/31/20211,238122267327N/A
12/31/20201,09189221280N/A
9/30/20201,02449180222N/A
6/30/20209492982118N/A
3/31/202090126112148N/A
12/31/20199112688129N/A
9/30/201985934109160N/A
6/30/20197671439131N/A
3/31/201976423-5104N/A
12/31/201873021-7678N/A
9/30/201860920-12536N/A
6/30/201862931-41102N/A
3/31/201864743N/A20N/A
12/31/201767945N/A8N/A
9/30/201780449N/A114N/A
6/30/201781463N/A21N/A
3/31/201783059N/A54N/A
12/31/201684072N/A58N/A
9/30/201681986N/A22N/A
6/30/201681087N/A78N/A
3/31/201672085N/A112N/A
12/31/201567185N/A97N/A
9/30/2015657103N/A16N/A
6/30/2015620111N/A-18N/A
3/31/2015572107N/A-39N/A
12/31/2014515103N/A14N/A
9/30/201445794N/A13N/A
6/30/201444090N/A35N/A
3/31/201443185N/A42N/A
12/31/201341981N/A30N/A
9/30/201340175N/A8N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 300181's forecast earnings growth is above the savings rate (2.9%).

Earnings vs Market: Insufficient data to determine if 300181's earnings are forecast to grow faster than the CN market

High Growth Earnings: Insufficient data to determine if 300181's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 300181's revenue is forecast to grow faster than the CN market.

High Growth Revenue: Insufficient data to determine if 300181's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 300181's Return on Equity is forecast to be high in 3 years time


Discover growth companies